Shots:
- The EC has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) to treat pts (≥6yrs.) with cystic fibrosis (CF), having ≥1 non-class I mutation in the CFTR gene; regulatory review is ongoing in Canada, Switzerland, Australia, & New Zealand
- In 2 H2H trials, Alyftrek + ivacaftor matched Kaftrio (ivacaftor/tezacaftor/elexacaftor) on ppFEV1 & showed superiority in reducing sweat chloride in CF pts
- Vanzacaftor & tezacaftor increase CFTR protein at the cell surface, while deutivacaftor enhances its function by boosting channel open probability to improve salt & water flow
Ref: Vertex Pharmaceuticals | Image: Vertex Pharmaceuticals| Press Release
Related News:- HanchorBio Out-Licenses HCB101 to Shanghai Henlius Biotech For ~$202M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
